MORRISVILLE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced it will participate in upcoming investor
Achieved YUTREPIA ® net product sales of $148.3 million for the full year 2025 with $90.1 million in the fourth quarter More than 3,600 unique prescriptions received and 2,900 patients treated to date since launch in June 2025 Ended 2025 with $190.7 million in cash and cash equivalents, an increase
MORRISVILLE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today that it will report its full year 2025 financial results on Thursday, March 5,
MORRISVILLE, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today the company will present three posters at the Pulmonary Vascular Research
Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025 Received more than 2,800 unique patient prescriptions since launch in June 2025 Generated more than $30 million of positive cash flow during the fourth quarter 2025
MORRISVILLE, N.C. , Jan. 07, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Dr. Roger Jeffs , Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 beginning at approximately 5:15 p.m.
MORRISVILLE, N.C. , Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today that members of the company’s executive leadership team will be providing
Recorded $51.7 million in net product sales of YUTREPIA™ as launch momentum continues Achieved profitability in the first full quarter of YUTREPIA sales More than 2,000 unique patient prescriptions and 1,500 patient starts to date Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C.
MORRISVILLE, N.C. , Oct. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its third quarter 2025 financial results on Monday, November 3,
MORRISVILLE, N.C. , Oct. 07, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that it will host a Research & Development Day (R&D Day) on Tuesday, October 28,